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Introduction 
Between 1955 and the end of 1967, the framework of clinical organ transplantation that exists today 
was established in a small number of centers in continental Europe, Great Britain, and North America. 
Here, I will describe the events during this period that led to human liver replacement. 
The genesis of liver transplantation 
Transplantation of all the major organs except the liver can be traced back to the early 1900s as 
described by the immunologist, Leslie Brent, and the Glasgow surgeon-historian David Hamilton 
(1,2). In contrast, liver transplantation was not mentioned in the literature until 1955. The first report 
appeared in Transplantation Bulletin, the forerunner of the current Transplantation (3). 
The auxiliary liver concept 
In a one-page article, C Stuart Welch of Albany Medical College, described the insertion of a hepatic 
allograft in the right paravertebral gutter of dogs, without disturbing the native liver (3). A more 
complete report was published in Surgery the following year (4). The auxiliary livers were 
revascularized by anastomosing the graft hepatic artery to the recipient aortoiliac system, and by end-
to-end anastomosis of the portal vein to the host inferior vena cava. The transplanted organs un-
derwent dramatic shrinkage, a finding that was incorrectly considered for most of the next decade to 
be a special feature of liver rejection. 
In 1957, Welch gave a lecture on his experimental operation during a visiting professorship at the 
University of Miami Medical School, where I was a general surgery resident. Because he had 
provided the auxiliary grafts with high flow input of systemic venous blood from the recipient IVC, 
Welch was convinced that his transplanted livers were optimally revascularizcd. 
Contrary to this assumption, I had been exploring the possibility that the first pass delivery of 
endogenous insulin from the pancreas to the liver by portal blood was important in metabolic 
crossregulation of the two organs. Evidence consistent with this hypothesis had come from studies of 
Eck's fistula (portacaval shunt) and reverse Eck's fistUla\f the hypothesis was correct, the Welch 
procedure was physiologically flawed. "'\ 
( ;F~/ 
Liver replacement 
To pursue the metabolic studies, I had developed a new method of total hepatectomy (7). The unique 
feature of the procedure was preservation of the retrohepatic inferior vena cava, as is done in today's 
piggy-back modification of liver transplantation. Reimplantation (autotransplantation) of the excised 
specimen was soon envisioned as an ideal way to study the portal physiology of an unequivocally 
denervated liver that was devoid of cryptic collateral arteries. Welch had obviated the need to 
anastomose multiple hepatic veins by including as part of his auxiliary allografts the short length of 
vena cava into which all of these hepatic veins empty and by connecting the upper end of the caval 
stump to the recipient vena cava. 
For liver replacement, it was easiest to excise the host retrohepatic vena cava along with the native 
liver, and to replace it with the comparable caval segment of an allograft. Restoration of caval 
continuity required end-to-end anastomoses: one at the diaphragm and the other below the liver. The 
performance of everting anastomoses in a confined space without the need for long vascular cuffs was 
made feasible by perfection of the intraluminal continuous suture technique used today. Hepatic 
arterial and biliary tract anastomoses were done with conventional methods.( q) ... E~---
At first, none of the animals survived the operation, but this was finally accomplished in June 1958, a 
few days after I moved from Miami to Northwestern University in Chicago. During the rest of the 
summer, the different kinds of liver revascularization studied in Miami in non-transplant models were 
systematically tested in allografts. Any alteration of the portal supply resulted in reduced survival. 
Although the findings were consistent with the original hypothesis that splanchnic venous blood 
contains liver-modulating factors, this issue was not fully resolved for another 15 years. 
Two administrative steps were taken at the end of that summer that ensured crucial research support 
for at least five years. The first was submission of a four-page NIH grant request for continued 
investigation of the liver's role in insulin and carbohydrate metabolism that included liver 
transplantation. In addition, my Northwestern chairman, Loyal Davis, nominated me for a Markle 
Scholarship; the purpose of these awards was to keep young faculty members in academic medicine in 
pursuit of some stipulated career objective. My proposal was the development of clinical liver 
transplantation. Just before Christmas, 1958, I was notified that the grant would be fully funded, and 
that I was to be a Markle scholar. 
Other early investigations 
Unknown to me in 1958, our attempts at liver replacements had been preceded by those ofa UCLA 
surgeon named Jack Cannon. In collaboration with William P Longmire Jr., Cannon had already made 
important basic observations about spontaneous tolerance in a neonatal chick model of skin trans-
plantation (10), and the facilitation of such tolerance with adrenal corticosteroids. The significance of 
this neglected work is discussed elsewhere." 
one-page review entitled "Brief oepo~ 
as Welch's report of the year before./ 
is liver transplant experiments were mentioned in a 
blished in 1956 in the same Transplantation Bulletin 
Cannon's description did not specify the species studied (presumably dog), and did not contain any 
detailed information. Cannon acknowledged Welch's report as his inspiration, and alluded "" .. to 
several successful operations ". (liver replacements) without survival of the 'patient'"" ". In a 
prophetic comment, he suggested that.... lithe liver undoubtedly has a great deal to do with the 
production of the homograft reaction and probably with the inception and maintenance of tissue 
specificity. Replacement transplantation of intact liver, therefore, might well lead to interesting 
results." 
In early 1959, I learned that a team headed by the late Francis D Moore .r. had begun the 
development of canine liver transplantation at the Peter Bent Brigham Hospital, Boston in June or 
July 1958, at the same time as my own first successful experiments. By the end of the summer of 
1958, the Boston team had done six liver replacements. These were reported in a 1959 issue of Trans-
plantation Bulletin (12). I first met Moore at the 1960 meeting of the American Surgical Association, 
where I discussed his presentation. By then, the cumulative total of canine liver replacements in the 
two laboratories had increased to 111-31 in Boston and 80 in Chicago. The results were published 
separately in 1960 in different journals (9, 12J. 
(g) ,3) 
Prerequisites for canine liver replacement 
The two prerequisites for peri operative survival of canine recipients were identified in both the 
Boston and Chicago laboratories. The first requirement was prevention of ischemic injury to the 
allograft. This was accomplished in Boston by immersing the liver in iced saline, a method 
independently used for preservation of intestinal and cardiac allografts by Lillehei and colleagues (14) 
and by Lower and Shumway (15) respectively. 
Our exploitation of hypothermia in Chicago reflected the influence of F John Lewis, professor of 
surgery at Northwestern, who, with his Fellow, Norman Shumway, had pioneered total body 
hypothermia for open-heart surgery at the University of Minnesota. The livers were cooled by 
intravascular infusion of chilled solutions, using thermal probes to monitor core temperatures. 
Interestingly, this now universal practice had never been done before, apparently because of fear of 
damaging the microcirculation. Better liver preservation was later obtained with infusates of differing 
osmotic, oncotic, and electrolyte composition: e.g. the Collins (16,17,18), Schalm, (19) and 
University of Wisconsin (UW) solutions (20,21) that originally were developed for kidney 
transplantation. 
The second prerequisite for successful canine liver transplantation was avoidance of damage to the 
recipient splanchnic and systemic venous beds, the drainage of which was obstructed during host 
,. 
hepatectomy and graft implantation. This was accomplished III both the Boston and Chicago 
laboratories with decompressing external venovenous bypasses. 
The pathology of liver rejection 
Until 1960, the kidney had been the only organ allograft whose unmodified rejection had been 
systematically studied. Most transplanted canine livers were destroyed in 5 to 10 days. The 
histopathologic studies were done in Chicago by Donald Brock (22) and in Boston by the late Gustav 
Dammin (23). Typically, a heavy concentration of mononuclear cells was seen in the portal tracts, and 
within and around the central veins. Hepatocyte necrosis was extensive. 
A curious observation was made, however, in our 63rd liver replacement experiment (22). The 
recipient's serum bilirubin reached a peak at n days and then progressively declined. The 
predominant histopathologic findings in the allograft by the 21 5t day were more those of repair and 
regeneration than of rejection. This was, to my knowledge, the first recorded exception to the existing 
dogma (based on skin graft research) that rejection, once begun, was inexorable. Five years later, the 
London pathologist, KA Porter, described similar findings in allografts of the first long-surviving 
canine liver recipients whose rejections had been reversed under immunosuppression in Denver (24). 
Because Porter's previous principal research had been kidney transplantation, he was now able to sort 
out features of rejection that were common to both organs (and various other allografts) in unmodified 
and immunosuppressed recipients, and to distinguish these changes from those that were specific to 
the different kinds of organ allografts. Under the leadership of AJ Demetris at the University of 
Pittsburgh, the field of clinical transplantation pathology rose from the base laid by the earlier 
workers. 
Variant liver transplant procedures 
The studies completed in Boston and Chicago defined, almost to the last detail, the liver replacement 
operation soon to be performed in humans. By the end of 1959, we also had developed the operation 
of multivisceral transplantation. Here, the allograft consisted of the liver and all of the other 
intraperitoneal organs (25,26). Essentially all of this work, and the development of liver 
transplantation, was done with the help of Harry A Kaupp Jr, a skillful general surgery resident. Two 
medical students (Robert Lazarus and Robert Johnson) rounded out the team. 
Two further observations about rejection were made in the multivisceral experiments that were 
validated much later in rodent studies (27) and in humans (28). First, rejection ofthe different organs 
transplanted with the liver was less than rejection of the individual organs transplanted alone. Second, 
-----_._------
there was histopathologic evidence of a widespread graft versus host reaction in recipient tissues 
without resulting in overt graft versus host disease. :J, '1 ) 
Multiviso"a1 transplrullation and as modifioations were applied in hu= 30 Y""" lai~ 
part of the conventional armamentarium of advanced organ transplant centers. When the operation 
was first presented at the Surgical Forum of the American College of Surgeons in October 1960, it 
was lampooned. In fact, all surgical research in transplantation of the 1958 to 1960 era was considered 
naive or wasteful by many critics and especially by basic immunologists, most of whom viewed the 
immune barrier as impenetrable. 
Immunosuppression by host cytoablation 
Just as this kind of surgical research in unmodified animals was losing momentum, it was 
dramatically revitalized by six successful human kidney transplantations performed between January 
1959 and February 1962, first by Joseph Murray in Boston (30) and then by the teams of Jean 
Hamburger (3 1) and Rene Kuss in Paris (32). Although "success" was defined as survival for at least 
1 year, the first two recipients (both offratemal twin kidneys) had continuous graft function for more 
than two decades without post-transplant immunosuppression. All six patients had been conditioned 
before transplantation with sublethal doses of 450R total body irradiation 
In an extension of the host preconditioning concept, the urologist, Willard Goodwin, performed six 
human kidney transplantations at UCLA in 1960-1961 in which host cytoablation was done with 
myelotoxic doses of cytoxan and methotrexate instead of total body irradiation (33). Although five of 
the six recipients came to an early death, Goodwin successfully reversed several rejections with 
prednisone during the 143-day survival of his third patient, whose kidney was donated by her mother 
in September 1960. This crucial observation was not reported until 1963 and was not known to us 
until then. 
In any event, it quickly became apparent that the Boston and French successes with cytoablation for 
kidney transplantation, remarkable though they were, would not be a bridge to liver transplantation. In 
our hands, total body irradiation precluded even peri operative, much less extended, survival of canine 
liver recipients (34). 
A sea change occurred with the arrival of the drug 6-mercaptopurine (6-MP). The key observation 
was that immune depression under 6-MP did not depend on overt bone marrow depression. The 
potential value of the drug in transplantation was first demonstrated in a rabbit skin graft model by 
Schwartz and Dameshek at Tuft's Medical School in Boston (35), and by the research team of Robert 
.' 
Good at the University of Minnesota (36). Prolongation of survival of canine kidney allografts under 
6-MP was reported soon after by Roy CaIne (in London) (37) and Charles Zukoski (in Richmond, 
USA) (38) ~ilf~f:t~ f:~ ... ~:l~:K 
By the end of 1960, CaIne (by now in Boston with Murray) and Zukoski (with David Hume in Rich-
, ~tained survival of canine kidney recipients for 100 days or more under treatment with 6-MP 
tS ~/ ~ven better results soon were reported by CaIne with azathioprine, an imidazole derivative of 
6-MP (39). When clinical kidney transplant trials with the new drugs were begun in Boston in 1960 
and 1961, the possibility of transplanting the human liver seemed close at hand. 
---------
Before William R Waddell left the Massachusetts General Hospital to become chair of surgery at the 
University of Colorado in Denver on July 1, 1961, where I joined him from Northwestern a few 
months later, we settled on cf~ical liver tranl>plantation as our highest priority. The plan was shelved 1 d' e.u ~ c.. II' "">'Ie. 04?\IC«f; M 
in early 1962 when we learned of disappointing results in the clinical trials of kidney transplantation 
"f1tct.7- fA/~e~r-~cKK"ClgEKreti II..,1"i f H'/,.j ~"D-f-~ v-
in Boston (40) and England (41)A A ray of hope could be found, however, in a report by the future 
Nobel laureate, Murray, in the September, 1962, issue of the Annals o/Surgery, (42) 
The article contained a description of a kidney that had functioned under azathioprine therapy for 120 
days, from the time of its transplantation from an unrelated donor on April 5, 1962, That kidney still 
functioned at 11 months and was destined to support dialysis-free life ofthe recipient for 17 month<~F 
A~s .}fe ",., patient @iva for as ibng.as tmqptliS,il% became the 7th human to 
survive more than 1 year after kidney transplantation and the first to do so without total body 
irradiation. 
In the meantime, we had obtained our own supply of azathioprine in the spring of 1962, and 
systematically evaluated it with the simpler canine kidney model rather than with liver 
transplantation, Many of the experiments were done with Tom Marchioro, subsequently a revered 
professor of surgery at the University of Washington (1967-1995), As in other laboratories, our 
yield of 1 DO-day canine kidney transplant survivors was small. 
~~~s . 
But two crucial findings were clinically relevant. First, canine kidney rejection developing under 
azathioprine invariably could be reversed with the addition of large doses of prednisone (43). The 
second key observation was that a mean survival of 36 days in dogs treated with azathioprine was 
almost doubled when the animals also were pretreated with the drug for 7 to 30 days. We committed 
to clinical trials of kidney and liver transplantation, in that order. Daily doses of aza oprine were to 
be given for 1 to 2 weeks before and after transplantation, with the addition of 
rejection. The renal program was opened in the autumn of 1962 . 
• I """DDDEFflfr~DDD~F $(1""'«' ~ ~K:gC 
'alii 'oK,",ls tl ,'J "g~If;KKK1~A:!:o: D!DII~ ~ ff-tyDfD~ wltt.,(Ja zKi!hf;D;~ w~ 
------- --------
rAt! te~DpD .. ,.ts 141'11, h'Wtll_,-{( c/-vKKr-r--KK"f_rgi~flIKgCc;KKcC-~gK~! '-.x. ,ec.r.r;-, s '.r:c.tJ,f" 
_ J ~< 
The two features of the adaptive immune response to allografts that eventually would make ~
transplantation of all kinds of organs feasible were promptly recognized. These were described in the 
title of the report of the first 10 Colorado kidney cases: the reversibility of rejection, and more 
importantly, the subsequent development of donor specific tolerance (44). "Tolerance," which 
referred to the time-related decline of need for maintenance immunosuppression, proved to be the 
correct word. 
Nine of the 46 recipients of kidney allografts from live-related donors (20%) remained dialysis-free 
for four decades, all but one with normal renal function throughout. Seven of the nine became 
immunosuppression-free for periods ranging from 2 to 38 years. One of the nine was recently 
murdered in a love triangle and had a normal transplanted kidney at coroner's autopsy! Those 
remaining bear eight of the nine longest surviving kidney allografts in the world today, including the 
• four longest. 
Human liver replacement: 1963 
Although the maximum follow-up of our first human renal recipient was only six months in the spring 
of 1963, our kidney experience triggered the decision to go forward with the infinitely more difficult 
trial ofliver transplantation (Table 1). The first attempt on March 1st 1963 was in an unconscious and 
ventilator-bound child with biliary atresia who bled to death during operation. The next two 
recipients, both adults, died 22 and 7 days after their transplantations on May 5 and June 3, 1963 for 
the indication of primary liver malignancies (Table 1). The two adults were found at autopsy to have 
extrahepatic micrometastases. The three failed cases were described in the December 1963 issue of 
Surgery. Gynecology and ObstetriCs (45). KI~tKfp} fmmunosuppressio~ was th,e same as that used for our kidney recimien~K-ereatment was begun 
ID~ > • 
with aiathiC'1prine with or without small doses of prednisone. The same therapy was continued after 
transplantation. With evidence of rejection, a high-dose course of prednisone was added. Rejections, 
which were monitored by serial serum bilirubin concentrations, were easily reversed. The transplanted 
livers retrieved at autopsy were remarkably free of rejection. 
Efficient allograft preservation was accomplished by transfemoral infusion of a chilled perfusate into 
the aorta of the non heart-beating donors after crossclamping the aorta at the diaphragm. The 
procedure was the same in principle as that of first stage of the 'flexible" multiple organ procurement 
operation currently used worldwide. There was very little ischemic damage to the allografts during 
their postmortem intervals of 2 to 8 hours, as indicated by modest increases in the liver injury tests. 
The various anastomoses were performed in the same way as in the canine experiments. The lethal 
mistake in the human cases was the use of passive venovenous bypasses. Emboli formed in the bypass 
tubing, migrated to the lungs, and caused or contributed to the deaths of all the 1963 Denver recipients 
who survived the operation. Overzealous correction of clotting abnormalities may have contributed to 
the complication. In much the same way as today, coagulation had been monitored with serial 
thromboelastograms and corrected with blood components and with epsilon amino caproic acid (an 
analogue of the currently used aprotinine). 
The supreme irony was that the venous decompression that had been critical in the dog experiments is 
not mandatory in most human liver recipients. The motor-driven venovenous bypass system, which 
was introduced in Pittsburgh in the 1980s made the procedure easier. In some centers, however, it 
now is used only selectively. 
The aftermath . ( ~F 
During the last half of 1963, two more attempts at liver transplantation were made in aenver~and one 
each in Boston (47) and Paris (48) (Table 1). Clinical activity then ceased for 3Yz years. The 
worldwide moratorium was voluntary. The decision to stop was reinforced, though, by widespread 
criticism of attempting to replace an unpaired vital organ with an operation that had come to be 
perceived as too difficult to ever be tried again. 
E£:~ I~ff"D:r: :!;;"-'i,,y Re'" ..-c. 
In contrast, kidney transplantation thrived at the University of Colorado. In 1964, a textbooIl'was pro-
duced based on our first 70 cases, emphasizing that renal transplantation had reached the level of a 
bonafide clinical service. At the beginning of 1963, the only three clinically active kidney transplant 
programs in the United States were at the long-standing Brigham center and the two opened in 1962: 
ours and David Hume's in Richmond, VA. One year later, nearly 50 kidney teams had started or were 
gearing up. A similar proliferation was going on throughout Europe. 
The liver moratorium 
Advances were made between January 1964, and the summer of 1967, most of which were applicable 
to all organs. 
Role ofHLA matching 
In a clinical collaboration with Paul Terasaki of UCLA, it was shown that the quality of HLA 
matching short of perfect compatibility had little association with kidney transplant outcome ~K By 
inference, desperately ill liver, heart, and other transplant candidates who could not wait for a well-
matched organ would not suffer a significant penalty by receiving a mismatched one. 
Development 0/ antilymphocyte globulin 
A second objective was to improve immunosuppression. Antilymphocyte globulin (ALG) was 
prepared from antilymphocyte serum (ALS) obtained from horses immunized against dog and human 
lymphoid cells. After its development and testing in dogs between 1963 and 1966, human-specfic 
ALG was introduced clinically in 1966 in combination with azathioprine and prednisone (the "triple 
drug cocktail"). E~DfF 
In the pre-clinical canine studies, the efficacy of dog-specific ALG had been demonstrated when it 
was given before, at the time of, or after kidney and liver transplantation ~FK It was noted that "". 
pretreatment [with ALG] did appear to be of value in the canine experiments, and was accordingly 
made part of the protocol used for patients" ~ ( 4- or ) 
Demonstration o/hepatic to!erogenicity 
The goal in Denver of restarting clinical liver transplantation was reflected by a growing kennel 
population of long surviving canine recipients, none of whom were treated with more than a 4-month 
course of azathiopri~? a few doses of ALG ~fK{n presenting the results of 143 canine liver 
replacements to the Society of University Surgeons in February 1965, I emphasized that 
"although the early recovery after liver homotransplantations has many hazards .... the frequency 
and rapidity with which dogs could be withdrawn from immunosuppression without an ensuing 
fatal rejection is remarkable ... The consistency of this state of host-graft nonreactivity and the 
rapidity with which it seemed to develop exceeds that reported after canine renal 
homotransplantations". (50) 
A year later, the French surgeon, Henri Gamier, reported (with Cordier) that a significant percentage 
of untreated outbred pig liver recipients did not reject their allografts (51). This observation promptly 
was confirmed and extended in England by CaIne at Cambridge (52), Peacock and Terblanche in 
Bristol (53), and us (54). Caine and coworkers subsequently demonstrated that the tolerance self-
induced by the liver extended to other tissues and organs from the liver donor, but not from third-
party pigs (55). 
Reassessment of the auxiliary liver graft 
Although our primary focus during the moratorium was on liver replacement, we also evaluated the 
ostensibly less radical auxiliary liver transplantation (Welch's operation). After showing that rejection 
could be completely prevented in some dogs with high doses of aZathioprine, it was proved that the 
acute atrophy of Welch's auxiliary livers was caused by depriving the allografts of liver supporting l.-----
constituents of splanchnic venous blood. (5.(,) 
These findings, which finalized the decision to proceed clinically with liver replacement, were not 
fullv explained until the mid-1970s. Eventually, it was establi~e;DiDt::t endogenous insulin was the 
. R~I~~ 
most important "hepatotrophic" factor in normal portal blood ( , , ). This was a decisive step in 
understanding the pathophysiology of Eck's fistula (portacaval shunt). 
Improved organ preservation 
The potential pitfall of organ preservation remained. It would still be necessary to obtain livers from 
non-heartbeating donors. To help surmount this difficulty, we developed an ex vivo perfusion system 
in 1966 and 1967 that permitted reliable preservation of canine livers for as long as a day. The effort 
was spearheaded by a young naval surgeon, Larry Brettschneider (59). Now, it was time to try again. 
Resumption of human liver replacement 
When the liver program reopened in July 1967, it had another weapon. This was an enthusiastic 2-
year NIH-supported Fellow from Stockholm named Carl Groth. Groth who was determined to 
succeed, and had no doubt that this would be possible, was a key member of both donor and recipient 
surgical teams. He also took charge of the post-transplant management team in a continuous vigil that 
lasted for many months. By the end of the year, multiple examples of prolonged human liver recipient 
survival had been produced, under triple drug immunosuppression: azathioprine, prednisone, and 
ALG (60) liillijji The liver transplant beachhead was reinforced by the opening of Roy CaIne's 
clinical program in Cambridge, England, in February 1968 (61). 
Transplantation of other extrarenal organs followed close behind the liver, usmg similar 
immunosuppression. Hearts were successfully transplanted in 1968 in Capetown by Barnard (62) and 
in Palo Alto by Shumway (63). In 1969, the first prolonged survival after human lung (64) and 
pancreas transplantation (65) was accomplished in Ghent and Minneapolis, respectively. But 
transplantation of the extrarenal organs, and especially of the liver, remained controversial for another 
decade, because of the high mortality. Swimming against the stream, the German and French teams of 
Rudolf Pichlmayr and Henri Bismuth entered the field in the early 1970s, as did the Dutch group of 
Rudi Krom later in the decade. 
The unusual tolerogenicity of the hepatic allograft previously demonstrated in dogs and pigs was 
evident in human liver recipients of the 1970s. In 1995, 12 of our 42 patients (28%) surviving from 
this era already had been off all immunosuppression for I to 17 years (66, 67). Since then, many of the 
remaining 30, who are now out to 33 years post-transplantation, also have stopped drugs and remain 
well. Such drug-free tolerance was almost unheard of with the other kinds of cadaveric organs. 
Advent of better drugs 
Despite such encouraging notations, the widespread use of the liver and other extrarenal organs was 
precluded for another decade by the high mortality. The outlook for all organs improved after 
cyclosporine was introduced clinically in England in 1978 by CaIne (68) and combined with 
prednisone in Denver one year later (69). Results further improved when tacrolimus was substituted 
for cyclosporine in the 1990s (70, 71). 
The increases in liver recipient survival with the two new drugs were particularly striking, but less 
dramatic gains were recorded with the other organs. By the end of the 20th century, transplantation of 
the liver and all of the other vital organs had become an integral part of sophisticated medical practice 
in every developed country in the world. 
. .. 
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Box 1: 
The. lesson is cle.aLHistoryisneither dull nor dead: It is a uniquely humansurvivaltool,aiding those 
inthc present by the ability to draw on the pasttomeet current needs,andtopreciictneedsyet to 
come. 
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Tables 
Table 1: The First Seven Human Liver Recipients 
Age Date City Disease Survival Cause of Death 
(yrs) (days) 
3 113/63 Denver Biliary atresia 0 Bleeding 
48 5/5/63 Denver Hepatoma, 22 Pulmonary emboli, sepsis 
cirrhosis 
68 3/6/63 Denver Duct cell 7 Pulmonary emboli 
carcinoma 
52 10/7/63 Denver Hepatoma, 6 GI bleeding, pulmonary 
cirrhosis emboli, liver failure 
58 16/9/63 Boston Colon metastases II Pneumonitis, hepatic 
abscess 
29 4110/63 Denver hepatoma 23 Sepsis, bile peritonitis, 
pulmonary emboli 




Figure 2 (formerly figure 8). 
Francis D Moore (1913-2001), professor of surgery at Harvard Medical College, and chief of 
surgery at the Peter Bent Brigham Hospital, Boston. Moore instituted a program of canine liver 
replacement in the summer of 1958, and attempted one of the human procedures done in 1963. 
Figure 3 (formerly figure 22). 
Photograph in the 1980s of Roy CaIne (1930 -) and currently of Charles Zukoski (1926 -). Both men 
tested 6-MP in the canine kidney transplant model in 1960 and reported encouraging results in the 
same year. 
Figure 4 (formerly figure 37). 
The first three human recipients to have prolonged survival after liver replacements in July and 
August 1967, The adult, Carl Groth, was then an NIH-supported Fellow in Denver who went on to 
found the department of Transplantation at the Karolinska Institute, Stockholm. 
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